|
BioPharmX
@
biopharmx
Menlo Park, CA
|
|
BioPharmX Corporation (NYSE American: $BPMX) is a specialty pharmaceutical company focused on optimizing drug delivery to benefit dermatology patients worldwide
|
|
|
243
Tweetovi
|
111
Pratim
|
1.743
Osobe koje vas prate
|
| Tweetovi |
|
BioPharmX
@biopharmx
|
9. ruj |
|
BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update bit.ly/2A4jw6U $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
18. srp |
|
Our new COO Mr. Bosacki previously served as President and CEO of Lautus Pharmaceuticals, a privately held pharmaceutical company focused on the #dermatology and aesthetics markets. Learn more about his experience here: bit.ly/2khSrc2 $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
17. srp |
|
Our new COO Mr. Bosacki previously served as Senior Vice President and General Counsel under BioPharmX CEO, Dr. David S. Tierney, at Oceana Therapeutics bit.ly/2khSrc2 $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
16. srp |
|
BioPharmX today announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical industry veteran, as its Chief Operating Officer bit.ly/2khSrc2 $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
27. lip |
|
BPX-04 was well-tolerated in a Phase 2b trial for moderate-to-severe papulopustular #rosacea and the efficacy and safety profile observed supports advancement into Phase 3 bit.ly/2XrDXYX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
26. lip |
|
"We are pleased with the overwhelmingly positive outcome on both the primary and secondary efficacy measures as well as the confirmation of the safety and cutaneous tolerability of our minocycline gel formulation," commented $BPMX CEO bit.ly/2XrDXYX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
25. lip |
|
BPX-04 successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear bit.ly/2XrDXYX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
25. lip |
|
BioPharmX today announced positive results from its Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular #rosacea bit.ly/2XrDXYX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
13. lip |
|
Approximately 40 to 50 million Americans suffer from #acne vulgaris. We are developing BPX-01, a topical version of minocycline, for these patients. Learn more: bit.ly/2XgqGix
|
||
|
|
||
|
BioPharmX
@biopharmx
|
11. lip |
|
BioPharmX Reports Fiscal First Quarter 2020 Financial Results bit.ly/2KdWd1t $BMPX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
11. lip |
|
#Acne is the most common skin condition that people experience. Most people develop acne to some degree during their lifetime. Understand the underlying causes of acne: cle.clinic/2JSXETd @ClevelandClinic
|
||
|
|
||
|
BioPharmX
@biopharmx
|
10. lip |
|
In a Phase 2b study, BPX-01 demonstrated a 58% reduction in inflammatory acne lesions. Learn about our development of a novel, proprietary topical minocycline gel for #acne vulgaris: bit.ly/2XgqGix $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
6. lip |
|
BPX-04 was designed to deliver minocycline topically for #rosacea patients looking to minimize systemic exposure to antibiotics. Learn more about the development program here: bit.ly/2XedOJv $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
5. lip |
|
#Rosacea is a common skin disease that can cause redness, swelling, and acne-like breakouts. @AADskin provides an overview: bit.ly/2I2XKG1
|
||
|
|
||
|
BioPharmX
@biopharmx
|
3. lip |
|
Our HyantX™ delivery system was designed to minimize the dosage required of a drug through enhanced targeted delivery, thereby limiting skin irritation associated with excess drug on the skin. Learn more from our CEO's latest presentation: bit.ly/2WbWLLT $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
31. svi |
|
BioPharmX is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal bit.ly/2WkSXIs $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
30. svi |
|
#Rosacea is a chronic dermatologic condition characterized by redness, stinging & inflammatory lesions primarily on the face. Learn more about our Ph 2b trial of BPX-04 which we anticipate reporting topline efficacy & safety results in July 2019 bit.ly/2QilAPX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
28. svi |
|
We've completed patient visits in our Phase 2b trial of BPX-04 for #rosacea, a chronic dermatologic condition characterized by redness, stinging and inflammatory lesions primarily on the face bit.ly/2QilAPX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
23. svi |
|
BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular #rosacea that leverages our HyantX™ topical delivery system. We recently announced our last patient visit in a Phase 2b trial: bit.ly/2QilAPX $BPMX
|
||
|
|
||
|
BioPharmX
@biopharmx
|
23. svi |
|
"We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said BioPharmX CEO bit.ly/2QilAPX $BPMX
|
||
|
|
||